Located at Deison Technology Park in Conroe, Texas, the official opening of its new 120,000 square-foot building is scheduled for October 7, 2022.
The CDMO specializes in production of plasmid DNA and RNA products for use in vaccines, immunotherapies, gene and cell therapies, and gene editing technologies. It has supported those industries with specialized CDMO services for over 20 years at its existing site in The Woodlands, Texas.
Demand for high quality and reliable plasmid manufacturing services has increased dramatically as DNA immunotherapy and gene therapies demonstrate success in clinical studies, said the developer. The new purpose-built facility at Conroe is designed to meet such demand.
“The new VGXI headquarters is ready to support our clients as they achieve successful late phase and commercial launch of their products,” said CEO Young Park. “Combined with our highly skilled and dedicated team, we are confident VGXI will continue to meet the growing industry demand for these next generation medicines.”
The new site has greatly expanded capabilities. It has four distinct manufacturing trains with state-of-the-art production equipment, flexible fermentation capacity in excess of 3000L, and expanded GMP fill/finish capabilities, outlined VGXI. Dedicated areas are also available for mRNA manufacturing and small-scale, rapid turnaround services for personalized therapies.
Qualification activities are fully underway in preparation for GMP production. To ensure a seamless transition and provide additional overflow capacity, the CDMO, which is a subsidiary of South Korean DNA vaccine developer, GeneOne Life Science, said the Woodlands site will remain fully operational.